Hypercalcemia after denosumab discontinuation in patients with osteoporosis: a systematic review and case report
Hypercalcemia after denosumab withdrawal in osteoporosis is rare, typically mild, and reflects rebound osteoclast activation. Sequential antiresorptive therapy is strongly recommended following denosumab discontinuation.
Authors
- Álex García Tellado (ORCID: https://orcid.org/0009-0009-9127-9898)
- Javier Pardo Lleidas
- Javier Queipo Menéndez
Institutions
- Universidad de Cantabria (ES)
- Marqués de Valdecilla University Hospital (ES)
- Instituto de Investigación Marqués de Valdecilla (ES)
Publication Details
- Journal
- Osteoporosis International
- Published
- 2026-01-22
- DOI
- https://doi.org/10.1007/s00198-026-07854-5
- Citations
- 1
- Primary Topic
- Bone health and treatments
- Type
- article
- Field-Weighted Citation Impact
- 24.20